VSTM241220P17000
- 0.00
- 0.000.00%
Verastem Newsroom
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Verastem Inc. Reports Increased Operating Expenses and Net Loss
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
Verastem Cuts FY24 EPS View to $4.17-$4.23 From $4.25-$4.35, Consensus $4.28
Verastem | 10-Q: Q3 2024 Earnings Report
Express News | Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Express News | Verastem Q3 Basic EPS USD -0.6
Press Release: Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem 3Q Loss/Shr 60c >VSTM
Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Verastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients...
Express News | Verastem Inc - FDA Filing Decision Expected Before End of 2024 With Potential for FDA Approval Decision by Mid-2025
Express News | Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology to Participate in Upcoming Investor Conferences
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib